GCM
AGN

Gladstone Capital Management’s Allergan plc AGN Stock Holding History

Gladstone Capital Management’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-18,523
Closed -$3.1M – 14
2019
Q2 		$3.1M Buy
+18,523
New +$2.56M 0.87% 11

Other funds holding AGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
LP
Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Gladstone Capital Management's AGN Position: Q3 2019 in Review

Gladstone Capital Management sold out of Allergan plc (AGN) in Q3 2019, closing a stake of 18,523 shares — an estimated $3.1M sold.

Gladstone Capital Management first reported a position in AGN in Q2 2019 and held it in 1 quarter. The position peaked at $3.1M in Q2 2019. 921 funds tracked by Wall St. Rank hold AGN as of Q3 2019.

  • Gladstone Capital Management reported no remaining Allergan plc position as of Q3 2019 after selling out during the quarter.
  • Gladstone Capital Management sold 18,523 Allergan plc shares in Q3 2019, an estimated $3.1M.
  • Gladstone Capital Management first reported a position in Allergan plc in Q2 2019 and held it in 1 quarter.
  • Gladstone Capital Management's Allergan plc position peaked at $3.1M in Q2 2019.
  • 921 funds tracked by Wall St. Rank held Allergan plc as of Q3 2019.

Based on Gladstone Capital Management's 13F filing for Q3 2019, filed 31 Oct 2019.